Table 2. HIV Disease and Medical Characteristics of the Human Study Sample.
| HIV+/METH−(n=31) | HIV+/METH+ (n=29) | F/χ2 | P | ||
|---|---|---|---|---|---|
| HIV disease characteristics | |||||
| AIDS (%) | 35.5% | 55.2% | 2.36 | 0.124 | — |
| Current ART use (%) | 56.7% | 60.7% | 0.10 | 0.754 | — |
| ARV regimen duration (months) | 26.2 (26.7) | 21.6 (18.3) | 0.33 | 0.568 | — |
| HIV duration (months) | 84.8 (98.8) | 123.8 (104.7) | 0.11 | 0.738 | — |
| Nadir CD4+ T cellsa (/μl) | 250 (125, 532) | 206 (97, 358) | 0.17 | 0.680 | — |
| Current CD4+ T cellsa (/μl) | 481 (304, 654) | 528 (354, 623) | 2.33 | 0.137 | — |
| Plasma HIV RNA >50 c/ml | 44.8% | 51.7% | 0.28 | 0.599 | — |
| CSF HIV RNA >50 c/ml | 39.1% | 47.4% | 0.29 | 0.591 | — |
Abbreviations: AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; CSF, cerebrospinal fluid; METH, methamphetamine; RNA, ribonucleic acid.
The data are expressed as mean (SD) unless otherwise indicated.
a
The data are expressed as median (interquartile range).